Multidisciplinary Approaches to Managing AEs with Bispecifics
February 7th 2025Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.
Multidisciplinary Approach to AE Management With Lorlatinib
February 5th 2025Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, highlighting multidisciplinary management strategies and integrating best practices into electronic medical records.
Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors
February 5th 2025Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.
QOL Considerations for Optimal Patient Outcomes with CAR-T Therapy
This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle support, balancing work during and after treatment, and effective supportive care measures.
Managing Neurotoxicities in CAR T: Clinical Approaches and Patient/Caregiver Education
This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to communicating risks with patients and caregivers.
Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics
January 31st 2025Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments significantly impacted patient outcomes.
Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients
January 29th 2025Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.
Decoding Symptoms: When Fatigue Speaks Volumes
January 16th 2025Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Navigating Treatment Options: Understanding Risks and Benefits
January 9th 2025Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
Empowering Patients in Treatment Planning
January 4th 2025Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the first consultation, and explore how Brandi communicated her treatment preferences to her care team, reflecting on her sense of inclusion in the decision-making process and areas for improvement.